SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-22-016042
Filing Date
2022-08-09
Accepted
2022-08-09 16:08:14
Documents
60
Period of Report
2022-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q virx-20220630.htm   iXBRL 10-Q 2869361
2 EX-31.1 virx-ex31_1.htm EX-31.1 13477
3 EX-31.2 virx-ex31_2.htm EX-31.2 13459
4 EX-32.1 virx-ex32_1.htm EX-32.1 6216
5 EX-32.2 virx-ex32_2.htm EX-32.2 6126
  Complete submission text file 0000950170-22-016042.txt   9106151

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT virx-20220630_lab.xml EX-101.LAB 482363
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT virx-20220630_cal.xml EX-101.CAL 38218
8 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT virx-20220630.xsd EX-101.SCH 58804
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT virx-20220630_def.xml EX-101.DEF 269375
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT virx-20220630_pre.xml EX-101.PRE 377546
54 EXTRACTED XBRL INSTANCE DOCUMENT virx-20220630_htm.xml XML 1494224
Mailing Address 2533 S COAST HWY 101 SUITE 210 CARDIFF CA 92007
Business Address 2533 S COAST HWY 101 SUITE 210 CARDIFF CA 92007 858-400-8470
Viracta Therapeutics, Inc. (Filer) CIK: 0001061027 (see all company filings)

IRS No.: 943295878 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-51531 | Film No.: 221148312
SIC: 2834 Pharmaceutical Preparations